REG - Beximco Pharmaceut - Notification of Preliminary Results and AGM

Beximco PharmaceuticalsAnnouncement

29/10/2020 07:00

RNS Number : 5130D
  
Beximco Pharmaceuticals Ltd
  
29 October 2020
  
 

29 October 2020
 
BEXIMCO PHARMACEUTICALS LIMITED
 
Notification of Preliminary Results and Annual General Meeting
 
Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces information for shareholders of the Company that the Board of Directors decided at their meeting held on 28 October 2020. Please see further detail as follows:
 



1.


To recommend the approval of the Financial Statements for the year ended 30 June, 2020


:


The Audited Financial Statements for the year ended 30 June 2020 have been approved. The full accounts are expected to be announced by 11 November 2020




2.


Date & Time of 44th AGM of the Company for the year ended 30 June, 2020


:


 19 December 2020 at 10.30 a.m.




3.


Venue of AGM


:


Digital Platform 




4.


Proposed Dividend for the year ended 30 June, 2020


:


 15% Cash Dividend (i.e. Tk. 1.50 per share) and 10% Stock Dividend (i.e. 10 shares for every 100 shares held). 




5.


Record date


:


 25 November 2020



 
 
Comparative Financial Disclosures:
 
Beximco Pharmaceuticals Limited (Stand-alone)
 



Particulars 


Year ended
30 June 2020


Year ended
30 June 2019




Net Profit after Tax


Tk. 3,363,399,873


Tk. 3,023,500,974




Earnings Per Share (EPS)


Tk. 8.29


Tk. 7.46




Net Asset Value (NAV)


Tk. 32,356,359,135


Tk. 29,600,843,240




Net Asset Value per share (NAVPS)


Tk. 79.78


Tk. 72.99




Net Operating Cash Flow Per Share (NOCFPS)


Tk. 12.85


Tk. 6.72



 
Beximco Pharmaceuticals Limited and its Subsidiaries (Consolidated)
 



Particulars 


Year ended
30 June 2020


Year ended
30 June 2019




Net Profit after Tax


Tk. 3,544,483,101


Tk. 3,040,402,954




Earnings Per Share (EPS)


Tk. 8.67


Tk. 7.48




Net Asset Value (NAV)


Tk. 32,495,120,607


Tk. 29,588,317,284




Net Asset Value per share (NAVPS)


Tk. 80.12


Tk. 72.96




Net Operating Cash Flow Per Share (NOCFPS)


Tk. 13.67


Tk. 7.30



 
 
 
For further information please visit www.beximcopharma.com  or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 586/11001, Ext.20080
 
Mohammed Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, ext.20030
 
Jamal Ahmed Choudhury, Executive Director (A&F)
Tel: +880 2 58611001, ext.20022
 
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0) 20 3368 3551 / 3555
 
SP Angel Corporate Finance LLP (Broker)
Vadim Alexandre / Abigail Wayne
Tel: +44 (0) 20 3470 0470
 
FTI Consulting
Simon Conway / Victoria Foster Mitchell
Tel: +44 (0) 20 3727 1000
 
Notes to Editors
 
About Beximco Pharmaceuticals Limited
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
 
Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 4,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NOAUWSORRNURUAA